<i>USH2A</i> mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer.

Yang, Dexin; Feng, Yuqin; Lu, Haohua; Chen, Kelie; Xu, Jinming; Li, Peiwei; Wang, Tianru; Xia, Dajing; Wu, Yihua

USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer. / USH2Açªååå¶ä»å³é®é©±å¨åºå çªåäºåä¸åç«æ£æ¥ç¹æå¶åå¨èºçæ£èä¸ä¸´åºèç³»çå³èç ç©¶.

Yang, Dexin; Feng, Yuqin; Lu, Haohua; Chen, Kelie; Xu, Jinming; Li, Peiwei; Wang, Tianru; Xia, Dajing; Wu, Yihua.

Afiliação

Yang D; Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Feng Y; Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center and UTHealth, Houston; Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Lu H; Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Chen K; Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Xu J; Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Li P; Department of Thoracic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Wang T; Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Xia D; Epidemiology Stream, Dalla Lana School of Public Health, University of Toronto, Toronto, M5S 2E8, Canada.
Wu Y; Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China. dxia@zju.edu.cn.

J Zhejiang Univ Sci B ; 24(2): 143-156, 2023 Feb 15.

Article em En, Zh | MEDLINE | ID: mdl-36751700

Assuntos

Carcinoma Pulmonar de Células não Pequenas; Proteínas da Matriz Extracelular; Inibidores de Checkpoint Imunológico; Neoplasias Pulmonares; Humanos; Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico; Carcinoma Pulmonar de Células não Pequenas/genética; Receptores ErbB/genética; Proteínas da Matriz Extracelular/genética; Inibidores de Checkpoint Imunológico/uso terapêutico; Neoplasias Pulmonares/tratamento farmacológico; Neoplasias Pulmonares/genética; Mutação; Inibidores de Proteínas Quinases/uso terapêutico; Proteínas Proto-Oncogênicas p21(ras)/genética; Resultado do Tratamento

Palavras-chave

Epidermal growth factor receptor (EGFR) mutation; Immune checkpoint inhibitor (ICI); Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation combined with tumor protein P53 (TP53) mutation; Lung cancer; Usher syndrome type-2A (USH2A) missense mutation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas da Matriz Extracelular / Carcinoma Pulmonar de Células não Pequenas / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En / Zh Revista: J Zhejiang Univ Sci B Assunto da revista: BIOLOGIA / MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google